Clinical trials: Syndrome X
Coronary Artery Disease, Coronary Stenosis
Measuring Blood Flow in Heart Vessels With a New Fibre Optic Sensor
The purpose of this investigation is to see if the newly developed "iKOs™ microcatheter" can safely and accurately measure flow and pressure within the heart arteries of 10 patients undergoing angiogram and pressure wire tests.
- Conditions
- Coronary Artery Disease, Coronary Stenosis, Coronary Microvascular Disease
- Trial name
- NCT05346458
- Testing
- Intra coronary rapid-exchange iKOs microcatheter intervention
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Queen Mary University of London
XIAP Deficiency, NLRC4-MAS
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension
This is an open-label extension study for patients previously enrolled in the AB2 Bio Ltd. ongoing Phase III clinical trial NLRC4/XIAP.2016.001 (IND N° 127953).
- Trial name
- NCT03512314
- Testing
- Tadekinig alfa
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 11 people
- Sponsor
- AB2 Bio Ltd.
X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
OBJECTIVES: I. Identify the molecular defects responsible for primary immunodeficiency disorders. II. Explore the mutations within each syndrome to better understand the genetics of these disorders. III.
- Conditions
- X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome, Wiskott-Aldrich Syndrome, Leukocyte Adhesion Deficiency Syndrome
- Trial name
- NCT00004341
- Where
- United States
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Obesity, Metabolic Syndrome X
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
Obesity is common (>30% of US adults), contributes to substantial morbidity and mortality, but is difficult to treat. Partly this is due to the transient, arduous and modest nature of lifestyle interventions.
- Trial name
- REVIVE (NCT01351753)
- Testing
- Metformin, Orlistat, Topiramate
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Iowa
COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
Long COVID or Postacute sequelae of COVID-19 infection (PASC) are increasingly recognised complications, defined by lingering symptoms, not present prior to the infection, typically persisting for more than 4 weeks.
- Conditions
- COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle, Remodeling, Vascular, Left Ventricular Dysfunction
- Trial name
- MYOFLAME-19 (NCT05619653)
- Testing
- Prednisolone, Losartan
- Where
- 5 sites in Austria, Germany
- Volunteers
- 279 people
- Sponsor
- Valentina Puentmann
Angina (Stable), Ischemic Heart Disease (IHD)
Angina After PCI: a Systems Medicine Study
Angina may persist or recur in patients treated by coronary angioplasty. The angioplasty involves a balloon treatment to open a blocked heart blood vessel and usually a stent (thin metal tube) is placed.
- Trial name
- CorMicA-PCI (NCT06854302)
- Testing
- Cardiovascular magnetic resonance imaging, Coronary physiology
- Where
- 4 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- NHS National Waiting Times Centre Board
Hemorrhagic Fever With Renal Syndrome
Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines
The purpose of this study is: To assess safety and tolerability of the HTNV and PUUV DNA vaccines, pWRG/HTN-M(x) and pWRG/PUUV-M(s2), administered intramuscularly using a TDS-IM electroporation device Secondary: To evaluate…
- Trial name
- HTNV/PUUV (NCT01502345)
- Testing
- Vaccine/device combination for prevention of HFRS
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Refractory Angina, Microvascular Angina
Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.
To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic…
- Conditions
- Refractory Angina, Microvascular Angina, Microvascular Coronary Artery Disease, Coronary Disease
- Trial name
- REMEDY-PILOT (NCT05492110)
- Testing
- Coronary sinus reducer, Invasive coronary physiology
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Imperial College London
Rett Syndrome
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome
- Trial name
- NCT04181723
- Testing
- Trofinetide
- Where
- 21 sites in United States
- Volunteers
- 187 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Exercise Therapy, Metabolic Syndrome X
Exercise Training Effects on Metabolic Syndrome: Interactions With Medication
To analyze the effects of different exercise training modalities (continuous, intervallic, and resistance training) on cardiorespiratory and metabolic fitness of metabolic syndrome patients when this training interacts with their…
- Conditions
- Exercise Therapy, Metabolic Syndrome X, Cardiorespiratory Fitness
- Trial name
- METSYND (NCT03019796)
- Testing
- MEDICATION AND EXERCISE TRAINING
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- University of Castilla-La Mancha
Trisomy 13, Trisomy 18
High Risk Multiple Gestation Study
The objectives of the clinical study are to demonstrate the accuracy of our proprietary algorithm method to determine the genetic health of the developing fetuses in a multiple gestation pregnancy from a maternal blood sample.
- Conditions
- Trisomy 13, Trisomy 18, Trisomy 21, Sex Chromosome Abnormalities
- Trial name
- NCT02278874
- Where
- 4 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
NLRC4-MAS, XIAP Deficiency
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
This is a Phase 3 study to assess the safety and efficacy of Tadekinig alfa in patients with monogenic, interleukin-18 (IL 18) driven autoinflammation due to Nucleotide-binding oligomerization domain, leucine-rich repeat and…
- Trial name
- NCT03113760
- Testing
- Tadekinig alfa, 0.9% sodium chloride
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 15 people
- Sponsor
- AB2 Bio Ltd.
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
The aim of this study is to establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for estimating: 1. Fractional flow reserve (FFR) and 2.
- Trial name
- SMARTFLOW (NCT07676097)
- Testing
- Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
- Where
- 9 sites in United States
- Volunteers
- 620 people
- Sponsor
- AngioInsight
Rett Syndrome
Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome
The RETT REVOLUTION trial is a placebo-controlled, single-blinded, exploratory study with patients serving as their own control ("N of 1" trial design) where the safety and efficacy of vorinostat in the treatment of Rett syndrome…
- Trial name
- NCT07150013
- Testing
- Vorinostat (SAHA)
- Where
- Colombia
- Volunteers
- 15 people
- Sponsor
- Unravel Biosciences, Inc.
Intermittent Claudication, Metabolic Syndrome X
Prevalence of Metabolic Syndrome in Patients With Intermittent Claudication
Metabolic syndrome, a group of cardiovascular risk factors related to insulin resistance, is a major determinant of cardiovascular mortality. Intermittent claudication is a symptom of an early stage of atherosclerosis.
- Trial name
- NCT00946868
- Where
- Brazil
- Volunteers
- 170 people
- Sponsor
- University of Sao Paulo
Depressive Symptoms, Metabolic Syndrome X
Reducing Disparities in Late Life Depression and Metabolic Syndrome
Linkages between depression and cardiovascular disease have been well documented. These appear to be more than associations, and may reflect causal relationships through a number of proposed pathways, including decreased physical…
- Conditions
- Depressive Symptoms, Metabolic Syndrome X, Overweight, Obesity
- Trial name
- BRIGHTEN-Heart (NCT01428791)
- Testing
- Generations older adult membership program, BRIGHTEN Heart Virtual Team intervention
- Where
- 2 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Wiskott-Aldrich Syndrome
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
An open follow up study of patients enrolled in the Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome and treated with autologous CD34+ cells transduced with the w1.6_hWASP_WPRE…
- Trial name
- WASFUP (NCT02333760)
- Testing
- Autologous CD34+ cells transduced with WASP lentiviral vector
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 10 people
- Sponsor
- Genethon
Chronic Granulomatous Disease
Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
The overall goal of the study is to investigate the functional, biochemical, and gene expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with Chronic Granulomatous Disease (CGD).
- Trial name
- NCT03548818
- Testing
- Interferon Gamma-1B
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Neutropenia
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are…
- Trial name
- NCT06056297
- Testing
- Mavorixafor
- Where
- 114 sites in United States, Argentina and 23 more
- Volunteers
- 176 people
- Sponsor
- X4 Pharmaceuticals
Fragile X Syndrome
A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome
This is a 2-part study, with each part having a unique set of objectives for male adolescents aged 9 to < 18 years with fragile X syndrome (FXS).
- Trial name
- NCT05163808
- Testing
- zatolmilast
- Where
- 17 sites in United States
- Volunteers
- 163 people
- Sponsor
- Tetra Discovery Partners